Beijing-based Sinovac has posted a positive preliminary snapshot of human data from the Phase I/II study of their vaccine for coronavirus, showing that the jab was able to safely spur protective antibodies in more than 90% of the volunteers involved.

The biotech reported Saturday that they had recruited 743 patients for the two-step trial, with 143 in Phase I and the rest in Phase II.

The neutralizing antibody seroconversion rate is above 90%, the company states, which concludes the vaccine candidate can induce positive immune response. Thats about all youre getting at this stage of the process, though, with little hard data in their statement to decipher.

Unlock this story instantly and join 83,800+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Here is the original post:
Eyeing a hot IPO market, 4DMT tops up its cash reserves and preps a leap into the clinic with bespoke gene therapy vectors - Endpoints News

Comments are closed.